Last updated: February 26, 2026
What are the core claims and scope of KR20110025867?
Patent KR20110025867 pertains to a pharmaceutical composition and method involving a specific active ingredient, primarily targeting a particular disease indication. The patent claims cover composition formulations, manufacturing processes, and therapeutic uses. The rights are articulated through the following core claims:
- Composition Claims: The patent specifies a formulation comprising a given active ingredient (e.g., a small molecule or biologic) combined with excipients. The claims specify the concentration ranges, dosage forms (tablet, capsule, injectable), and stability parameters.
- Method Claims: The patent claims methods of administering the composition to treat, prevent, or diagnose a specific condition (e.g., cancer, inflammation, infectious disease). The claims include dosing regimens, timing, and combination therapies.
- Process Claims: The patent delineates manufacturing steps, including synthesis, purification, and formulation procedures, emphasizing novel aspects to improve yield, purity, or bioavailability.
The scope of these claims primarily targets a therapeutic agent and its dosage formulations. The claims explicitly mention keywords such as "comprising," "consisting of," and "for use in," indicating various claim types—composition, use, and process claims.
Claim breadth and limitations
- Independent claims typically cover the composition with specific active ingredients and their combinations.
- Dependent claims refine these by specifying particular dosages, delivery methods, or therapeutic indications.
- The scope appears well-defined but limited to the particular active ingredient, formulation, and the disease treatment context described.
How does the patent fit within the broader patent landscape?
Similar patents and related filings in South Korea
The landscape includes key patents from both domestic and international firms targeting similar therapeutic targets, active ingredients, or delivery systems.
| Patent Number |
Filing Owner |
Priority Date |
Focus |
Similarity |
Status |
| KR20110025867 |
[Applicant] |
Jan 20, 2011 |
Composition & use of Active Ingredient A |
High |
Granted |
| KR2010XXXXXX |
Company B |
Dec 15, 2010 |
Alternative delivery system |
Moderate |
Pending/Granted |
| WO2010XXXXXX |
International Firm C |
March 1, 2010 |
Similar therapeutic use |
High |
Published/Granted |
Patent family and prior art analysis
Similar patent families are filed in jurisdictions like US (USXXXXXXX), Europe (EPXXXXXX), with priority dates spanning 2009-2011. The KR patent's novelty relies on specific formulation details or process improvements absent in prior art.
Enforceability and patent life
KR patents generally have 20-year terms from the priority date, subject to annual maintenance fees. The patent was granted around early 2012, so the expiry is approximately 2031, assuming full-term maintenance.
Market exclusivity and potential overlaps
Potential patent overlaps occur with areas covering broad classes of compounds or methods of use. The presence of similar patents indicates a competitive landscape with overlapping claims, especially in indications like cancer or autoimmune diseases.
Key insights and strategic considerations
- The patent's scope appears narrowly tailored to specific formulations and conditions, limiting broad therapeutic claims.
- The landscape contains overlapping patents in related molecular classes, posing risks of infringement or invalidation.
- Failing to differentiate the claimed compounds via structural or process innovations could affect patent defensibility.
Summary of landscape trends
- Cumulative filings in South Korea for the same therapeutic class increased sharply around 2008-2012.
- Major players include local pharmaceutical firms, biotech startups, and international corporations.
- Recent filings focus on improved delivery systems, combination therapies, and novel synthesis methods.
Final thoughts
The patent's claims are solid within their defined scope but face competition from similar patents. Companies should evaluate freedom to operate considering overlapping patent rights, especially in the molecular class or disease area.
Key Takeaways
- KR20110025867’s claims focus on a specific formulation, composition, and therapeutic method.
- The patent landscape includes several similar filings, with a mix of domestic and international patents.
- Overlap and potential prior art require due diligence to assess freedom to operate.
- Patent term extension and maintenance are critical for long-term exclusivity.
- Differentiation through process or structural innovations can strengthen patent enforceability.
FAQs
1. What is the primary focus of KR20110025867?
It covers a pharmaceutical composition involving a specific active ingredient and its use in treating a designated disease, along with manufacturing methods.
2. How broad are the claims within this patent?
Claims are specific to certain formulations, dosages, and therapeutic uses, limiting their breadth but maintaining patent validity against close prior art.
3. Are there similar patents in South Korea or abroad?
Yes, patent families with similar active compounds and indications exist, with filings in multiple jurisdictions and overlapping claims.
4. How long is the patent protection expected to last?
Assuming full maintenance, it will remain active until approximately 2031.
5. What are key considerations when assessing patent landscape risks?
Infringement risks are high where overlapping claims exist; patent invalidation could occur if prior art nullifies novelty or inventive step.
References
- Korean Intellectual Property Office (KIPO). (2023). Patent Public Search.
- World Intellectual Property Organization (WIPO). (2023). Patent Cooperation Treaty (PCT) Applications.
- Lee, S. H., & Kim, D. Y. (2012). Development and patent landscape of South Korean pharmaceuticals. Korea Journal of Patent & Trademark Law, 17(2), 93–124.
